Renowned Physician-Scientist Brings Significant Expertise as a Pioneer in the Fields of Leukemia Research and Molecular GeneticsContinue reading
Author Archive: AZBio
Mayo Clinic purchases 228-acre land parcel in North Phoenix for further patient care expansion and the development of a biotechnology corridor
PHOENIX — Mayo Clinic has acquired 228 acres of land adjacent to its campus in North Phoenix, securing the ability to expand its patient-centered model of care and paving the way to develop a transformative biotechnology corridor.Continue reading
Scintillation Nanotechnologies, Inc. to exhibit nanoparticle scintillator platform at SLAS 2022 International Conference and Exhibition.
Tucson-based Scintillation Nanotechnologies, Inc. has been selected by the Society for Laboratory Automation and Screening (SLAS) to be included on “Innovation AveNEW” at the society’s upcoming 2022 International Conference and Exhibition. The company – a startup founded to commercialize inventions stemming from research at the University of Arizona – has developed next generation nanoparticles for the detection of radiolabeled compounds directly in aqueous samples, eliminating the need for extensive sample preparation and sample destruction that are experienced with competing products. The unique chemical and physical properties of the company’s aquaSCINTTM and nanoSPATM products give researchers unprecedented insight into drug uptake, binding, and distribution while saving time and reducing costly hazardous waste . Continue reading
Arizona Science Center Names Guy Labine as New President and CEO
International Leader Comes to Arizona from Science North located in Ontario, Canada
Applications open for Helios Scholars at TGen and TGen Bioscience Leadership Academy
Summer education programs focus on high school through college graduate studentsContinue reading
Access Key Members of the Investment Community With Your Application to Start-Up Stadium
The goal of Start-up Stadium is to increase your start-ups’ engagement and visibility with investors, state and regional affiliates, and early-stage companies at the beginning of their life-cycle.Continue reading
Three Arizona Projects Selected for Round One of the EDA’s “Build Back Better Regional Challenge”
60 Regional Coalitions will each compete for up to $100 Million in American Rescue Plan Funding to Rebuild America’s Communities. View the Arizona Based Project Summaries:
- City of Tucson: Southern Arizona Coalition for Climate Adaptation and Resilience: A cluster to drive sustainable agriculture, preserve water resources and develop clean energy
- Greater Phoenix Economic Council: New Healthcare Innovation Economy: Greater Phoenix Health Technology Innovation Moonshot
- Hopi Utilities Corporation: Transitioning Hopi Economy from Coal to Renewables with Focus on Job Training and Local Opportunities
Investing In Innovation: An Arizona Opportunity
On Thursday, December 9, 2021, over 160 life science executives, patient advocates, and business leaders gathered to honor the policy makers who are blazing the trail for the growth of Arizona’s life science sector at the annual AZBio Trailblazers Luncheon and learned why investing in innovation is an Arizona opportunity. Continue reading
HTG Announces Major Sales Milestone for HTG Transcriptome Panel
Recognizes More Than $1 Million of HTP Revenue Through November 2021Continue reading
uniQure and CSL Behring Announce Primary Endpoint Achieved in HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B
- Largest gene therapy study in hemophilia B achieved primary endpoint of non-inferiority in annualized bleeding rate after stable Factor IX (FIX) expression, assessed at 18 months following a single dose of etranacogene dezaparvovec
- Etranacogene dezaparvovec also achieved secondary endpoint demonstrating statistical superiority in reduction of annualized bleeding rate compared to baseline FIX prophylactic therapy
- Stable and durable FIX levels with mean FIX activity of 36.9 percent of normal in full study population at 18-months, compared to a mean of 39.0 percent of normal at 6 months
- Manufacturing operations supporting process validation of etranacogene dezaparvovec successfully completed by uniQure